Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03727646 · ClinicalTrials.gov registry record · Early Phase 1
Nicotinamide Riboside in LVAD Recipients
A Early Phase 1 study of Heart Failure，Congestive and Mitochondrial Alteration, sponsored by University of Washington.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT03727646 is a Early Phase 1 study of Heart Failure，Congestive and Mitochondrial Alteration that has completed, run by University of Washington. The registered enrollment target is 5 participants, below the 1,027-participant average among 5 other Heart Failure，Congestive trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03727646, a Early Phase 1 study of Heart Failure，Congestive and Mitochondrial Alteration, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
While preliminary data show that oral nicotinamide riboside (NR) supplementation increases myocardial levels of oxidized nicotine-adenine dinucleotide (NAD+) levels in mice, there has been no direct evidence that suggests oral NR increases NAD+ levels or improves mitochondrial function in human hearts. This Pilot Study is designed to obtain feasibility data for a planned, larger study testing the hypothesis that oral NR supplementation will increase myocardial NAD+ levels and improve cardiomyocyte mitochondrial function in participants with advanced heart failure planned for elective left ventricular assist device (LVAD) implantation. To demonstrate safety and feasibility of NR in this patient population, the investigators propose to enroll 5 participants planned for LVAD implantation in a Pilot Study of NR in which participants will receive NR, up-titrated over 3 days to a final NR dose of 1000mg twice daily. Blood and myocardial tissue analyses collected previously from age- and gender-matched LVAD recipients will serve as controls.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Nicotinamide riboside
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-09-26 |
| Est. Completion | 2018-11-26 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03727646
The ClinicalTrials.gov registry entry for NCT03727646 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,027-participant average among 5 other Heart Failure，Congestive trials with a reported enrollment target (100% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Heart Failure，Congestive appearing as the primary indexed condition, and to 1 intervention - of which Nicotinamide riboside is the first listed.
NCT03727646 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT03727646 about?
NCT03727646 is a clinical study titled "Nicotinamide Riboside in LVAD Recipients". While preliminary data show that oral nicotinamide riboside (NR) supplementation increases myocardial levels of oxidized nicotine-adenine dinucleotide (NAD+) levels in mice, there has been no direct evidence that suggests oral NR increases NAD+ levels or improves mitochondrial function in human hear...
What is the current status of trial NCT03727646?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2018-09-26. Estimated completion is 2018-11-26.
What conditions does trial NCT03727646 study?
This clinical trial studies the following conditions: Heart Failure，Congestive, Mitochondrial Alteration, Heart Failure New York Heart Association Class IV.
What interventions are being tested in trial NCT03727646?
The interventions under investigation include: Nicotinamide riboside (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03727646?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03727646 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure，Congestive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The ROle of Compression StocKings in Heart Failure Patients
RECRUITING · NA
-
HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection
ACTIVE NOT RECRUITING
-
AB-1002 in Patients With Class III Heart Failure
ACTIVE NOT RECRUITING · Phase 1
-
Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)
COMPLETED · NA
-
Hemodynamic-GUIDEd Management of Heart Failure
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.